PMID- 25859685
OWN - NLM
STAT- MEDLINE
DCOM- 20160129
LR  - 20150609
IS  - 1938-2405 (Electronic)
IS  - 0191-3913 (Linking)
VI  - 52
IP  - 3
DP  - 2015 May-Jun
TI  - Spectral-Domain OCT Analyses of Macular Changes After Ranibizumab Therapy for 
      Type 1 Retinopathy of Prematurity.
PG  - 152-8
LID - 10.3928/01913913-20150326-12 [doi]
AB  - PURPOSE: To investigate the clinical and macular spectral-domain optical 
      coherence tomography (SD-OCT) findings after intravitreal ranibizumab treatment 
      for type 1 retinopathy of prematurity (ROP). METHODS: Eighteen eyes of 10 
      premature infants with type 1 ROP were retrospectively studied. All eyes were 
      treated with intravitreal ranibizumab as monotherapy. Macular SD-OCT was 
      performed before and after intravitreal ranibizumab therapy using a portable 
      SD-OCT machine; the follow-up images were taken 1 day, 1 week, 1 month, and 2 
      months after therapy. RESULTS: Among the 10 infants, there were six males and 
      four females. Mean central foveal thickness before and 2 months after 
      intravitreal ranibizumab was 292.5 +/- 61.4 and 171.6 +/- 21.7 microm, respectively. 
      Differences were statistically significant (P = .01). Sixteen eyes of eight 
      patients had macular edema before treatment. Two eyes of two patients developed a 
      crack in the outer hyperreflective line on SD-OCT corresponding with retinal 
      pigment epithelium with serous retinal detachment 1 day after treatment. Macular 
      edema regressed in all patients 2 months after intravitreal ranibizumab therapy. 
      Mean follow-up time was 11.4 +/- 1.5 months. No recurrence was seen except in both 
      eyes of one patient treated with intravitreal ranibizumab monotherapy. 
      CONCLUSIONS: Intravitreal ranibizumab injection is effective for the treatment of 
      type 1 ROP as a monotherapy agent; however, macular changes not seen with 
      indirect ophthalmoscope may develop.
CI  - Copyright 2015, SLACK Incorporated.
FAU - Erol, Muhammet Kazim
AU  - Erol MK
FAU - Coban, Deniz Turgut
AU  - Coban DT
FAU - Ozdemir, Ozdemir
AU  - Ozdemir O
FAU - Tunay, Zuhal Ozen
AU  - Tunay ZO
FAU - Bilgin, Ahmet Burak
AU  - Bilgin AB
FAU - Dogan, Berna
AU  - Dogan B
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20150331
PL  - United States
TA  - J Pediatr Ophthalmol Strabismus
JT  - Journal of pediatric ophthalmology and strabismus
JID - 7901143
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Female
MH  - Gestational Age
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Infant, Premature
MH  - Infant, Very Low Birth Weight
MH  - Intravitreal Injections
MH  - Macula Lutea/*pathology
MH  - Macular Edema/*drug therapy
MH  - Male
MH  - Ranibizumab/*therapeutic use
MH  - Retinopathy of Prematurity/*drug therapy
MH  - Retrospective Studies
MH  - *Tomography, Optical Coherence
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors
MH  - Visual Acuity
EDAT- 2015/04/11 06:00
MHDA- 2016/01/30 06:00
CRDT- 2015/04/11 06:00
PHST- 2014/10/09 00:00 [received]
PHST- 2015/01/13 00:00 [accepted]
PHST- 2015/04/11 06:00 [entrez]
PHST- 2015/04/11 06:00 [pubmed]
PHST- 2016/01/30 06:00 [medline]
AID - 10.3928/01913913-20150326-12 [doi]
PST - ppublish
SO  - J Pediatr Ophthalmol Strabismus. 2015 May-Jun;52(3):152-8. doi: 
      10.3928/01913913-20150326-12. Epub 2015 Mar 31.